Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251175 | 1.00 | SRD5A2 (0.61) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL3102374 | 0.89 | CYP3A4 (0.59) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL3102365 | 0.89 | CYP3A4 (0.59) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL23458225 | 0.89 | CYP3A4 (0.64) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL11821082 | 0.88 | SHBG (0.68) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL11232680 | 0.87 | SRD5A2 (0.56) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL23458371 | 0.84 | LMNA (0.66) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL8340076 | 0.83 | SHBG (0.48) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL8340073 | 0.83 | SHBG (0.48) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 | |
| SCHEMBL11873307 | 0.83 | SRD5A2 (0.45) | SRD5A2SHBGCYP19A1CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992431-B2 | Inserter | BAYER OY (FI) | 2024-05-28 | — | — | US | claimed |
| US-20210298942-A1 | INSERTER | BAYER OY (FI) | 2021-09-30 | — | — | US | claimed |
| US-10561524-B2 | Inserter | BAYER OY (FI) | 2020-02-18 | — | — | US | claimed |
| EP-3501543-A1 | METHOD FOR MANUFACTURING VAGINAL DRUG DELIVERY SYSTEMS USING A THREE DIMENSIONAL PRINTER | Delim Cosmetics & Pharma S.r.l. (IT) | 2019-06-26 | — | — | EP | claimed |
| US-20170196728-A1 | INSERTER | BAYER OY (FI) | 2017-07-13 | — | — | US | claimed |
| US-20100322884-A1 | METHOD AND COMPOSITION FOR TRANSDERMAL DRUG DELIVERY | ACRUX DDS PTY LTD | 2010-12-23 | — | — | US | claimed |
| EP-1402924-B1 | Use of a compound for the treatment of heart hypertrophy | FRAUNHOFER GES FORSCHUNG (DE) | 2008-12-31 | — | — | EP | claimed |
| EP-1904031-A2 | A SUBSTANTIALLY WATER-FREE PRESSURISED PROPELLANT MIXTURE | THERAPICON SRL (IT) | 2008-04-02 | — | — | EP | claimed |
| US-20070292479-A1 | Film-shaped drug forms for use in the oral cavity (wafers) | BAYER SCHERING PHARMA AG (DE) | 2007-12-20 | — | — | US | claimed |
| WO-2006122905-A2 | A SUBSTANTIALLY WATER-FREE PRESSURISED PROPELLANT MIXTURE | THERAPICON SRL (IT) | 2006-11-23 | — | — | WO | claimed |
| EP-1282402-B1 | STABILIZED AQUEOUS SUSPENSIONS FOR PARENTERAL USE | PHARMACIA ITALIA SPA (IT) | 2005-12-21 | — | — | EP | claimed |
| US-6495534-B2 | Stabilized aqueous suspensions for parenteral use | PHARMACIA & UPJOHN SPA (IT) | 2002-12-17 | — | — | US | claimed |
| WO-2025226786-A1 | METHODS AND COMPOSITIONS COMPRISING WETTABLE ELECTROSPUN MATRIX | POLY-MED, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250289909-A1 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | PMIDG LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| US-12351656-B2 | Functionalized and crosslinked polymers | PMIDG, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| EP-0597071-A1 | ANDROGENS FOR STIMULATING THE CENTRAL NERVOUS SYSTEM AND FOR TREATING OSTEOPOROSIS | ARROWDEAN LTD. (IE) | 1994-05-18 | — | — | EP | disclosed |
| EP-0597071-A1 | ANDROGENS FOR STIMULATING THE CENTRAL NERVOUS SYSTEM AND FOR TREATING OSTEOPOROSIS | ARROWDEAN LTD. (IE) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993024128-A1 | ANDROGENS FOR STIMULATING THE CENTRAL NERVOUS SYSTEM AND FOR TREATING OSTEOPOROSIS | MATTERN ET PARTNER PHARMAZEUTISCHE ENTWICKLUNGS- UND HANDELSGES. MBH (DE) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024128-A1 | ANDROGENS FOR STIMULATING THE CENTRAL NERVOUS SYSTEM AND FOR TREATING OSTEOPOROSIS | MATTERN ET PARTNER PHARMAZEUTISCHE ENTWICKLUNGS- UND HANDELSGES. MBH (DE) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100322884-A1 | METHOD AND COMPOSITION FOR TRANSDERMAL DRUG DELIVERY | CUTA, TSLP, CERT1 | SRD5A2 1338/4885SHBG 252/4885CYP19A1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.